Format

Send to

Choose Destination
Neurology. 2005 Apr 12;64(7):1270-2.

An open label study of the effects of rituximab in neuromyelitis optica.

Author information

1
Multiple Sclerosis Center, University of California, San Francisco 94117, USA. bcree@itsa.ucsf.edu

Abstract

Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight patients were relapse free and median attack rate declined from 2.6 attacks/patient/year to 0 attacks/patient/year (p = 0.0078). Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013).

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center